Inovio Announces First Patient Dosed in Trial to Determine PENNVAX®-GP’s Ability to Induce Remission of HIV Infection
PLYMOUTH MEETING, Pa., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that the first participant has been dosed with PENNVAX®-GP in a randomized clinical trial that will evaluate its ability to drive remission …